2. Metabolic Enzyme/Protease Anti-infection Apoptosis
  3. Endogenous Metabolite Bacterial Apoptosis
  4. p-Coumaric acid

p-Coumaric acid  (Synonyms: trans-4-Hydroxycinnamic acid)

Cat. No.: HY-N0351 Purity: 99.83%
SDS COA Handling Instructions

Molarity Calculator

p-Coumaric acid (trans-4-Hydroxycinnamic acid) is an isomer of cinnamic acid with oral activity. p-Coumaric acid inhibits cell proliferation and promotes apoptosis. p-Coumaric acid has antibacterial, anti-inflammatory, antioxidant and anti-tumor activities.

For research use only. We do not sell to patients.

p-Coumaric acid Chemical Structure

p-Coumaric acid Chemical Structure

CAS No. : 501-98-4

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
100 mg USD 60 In-stock
1 g USD 84 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of p-Coumaric acid:

p-Coumaric acid Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE p-Coumaric acid

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

p-Coumaric acid (trans-4-Hydroxycinnamic acid) is an isomer of cinnamic acid with oral activity. p-Coumaric acid inhibits cell proliferation and promotes apoptosis. p-Coumaric acid has antibacterial, anti-inflammatory, antioxidant and anti-tumor activities[1][2][3][4].

IC50 & Target

Microbial Metabolite

 

Human Endogenous Metabolite

 

In Vitro

p-Coumaric acid (1 or 3 μg/mL, 24, 48, 72 h) can significantly inhibit the proliferation of human and mouse melanoma cells in vitro and promote cell apoptosis[1].
p-Coumaric acid (10-80 μg/mL) shows antibacterial activity against both gram-negative and Gram-positive bacteria, and MIC values for Escherichia coli, Streptococcus dysenteriae and Salmonella typhimurium are 80, 10 and 20 μg/ml[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

p-Coumaric acid Related Antibodies

Cell Proliferation Assay[1]

Cell Line: A375, B16
Concentration: 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 mM
Incubation Time: 24, 48 h
Result: Inhibited the proliferation of A375 and B16 cells The IC50 values on A375 cells were 4.4 mM and 2.5 mM , and the IC50 values on B16 cells were 4.1 mM and 2.8 mM in 24 and 48 h, respectively.

Cell Cycle Analysis[1]

Cell Line: A375, B16
Concentration: 1.5, 2.5, 3 mM;2, 3, 4 mM
Incubation Time: 24 h
Result: Increased the S phase proportion in A375 cells and the G0/G1 phase proportion in B16 cells.

Western Blot Analysis[1]

Cell Line: A375, B16
Concentration: 1.5, 2.5, 3 mM;2, 3, 4 mM
Incubation Time: 24 h
Result: Reduced the expression levels of CDK2 and Cyclin A in A375 cells and the levels of CDK2 and Cyclin E in B16 cells.
Decreased the levels of caspase-3 and caspase-9 and increased the levels of cleaved caspase-3 and cleaved caspase-9.
Downregulated Bcl-2 and upregulated Bax, Apaf1, and cytoplasmic Cyto-C levels.
In Vivo

p-Coumaric acid (50, 100, 200 mg/kg, suspended in 0.5% carboxymethyl cellulose (CMC), was administered daily via gastric cannula for 15 weeks) It has a protective effect on colon pretumor induced by 1,2 dimethylhydrazine (DMH) in rats[3].
p-Coumaric acid (15, 100 mg/kg, oral) alleviates nephrotoxicity induced by Doxorubicin (HY-15142A) in rats by inhibiting oxidative stress, inflammation and apoptosis[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DMH-induced colonic preneoplastic lesions in rats[3]
Dosage: 50, 100, 200 mg/kg
Administration: suspended in 0.5% carboxymethylcellulose (CMC) and administered every day via intragastric intubation
Result: Reduced the polyp incidence to 71.42%, 57.14% and 42.85% respectively.
Reduced the ACF and DACF in a dose-dependent manner and the β– catenin immune activity.
Decreased levels of TBARS and increased levels of SOD, CAT and GPx.
Decreased the activity of β-glucuronidase, and mucinase.
Animal Model: Doxorubicin-induced nephrotoxicity rats[4]
Dosage: 15, 100 mg/kg
Administration: p.o.
Result: Decreased serum creatinine, BUN and lipid peroxidation, IL-1β and TNF-α.
Decreased the number of TUNEL-positive cells.
Molecular Weight

164.16

Formula

C9H8O3
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(O)/C=C/C1=CC=C(O)C=C1
Structure Classification
Initial Source

S. cerevisiae strain
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

RT, stored under nitrogen

In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (152.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.0916 mL 30.4581 mL 60.9162 mL
5 mM 1.2183 mL 6.0916 mL 12.1832 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (12.67 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (12.67 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.83%

SDS (393 KB)

COA (244 KB) LCMS (96 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 6.0916 mL 30.4581 mL 60.9162 mL 152.2904 mL
5 mM 1.2183 mL 6.0916 mL 12.1832 mL 30.4581 mL
10 mM 0.6092 mL 3.0458 mL 6.0916 mL 15.2290 mL
15 mM 0.4061 mL 2.0305 mL 4.0611 mL 10.1527 mL
20 mM 0.3046 mL 1.5229 mL 3.0458 mL 7.6145 mL
25 mM 0.2437 mL 1.2183 mL 2.4366 mL 6.0916 mL
30 mM 0.2031 mL 1.0153 mL 2.0305 mL 5.0763 mL
40 mM 0.1523 mL 0.7615 mL 1.5229 mL 3.8073 mL
50 mM 0.1218 mL 0.6092 mL 1.2183 mL 3.0458 mL
60 mM 0.1015 mL 0.5076 mL 1.0153 mL 2.5382 mL
80 mM 0.0761 mL 0.3807 mL 0.7615 mL 1.9036 mL
100 mM 0.0609 mL 0.3046 mL 0.6092 mL 1.5229 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

p-Coumaric acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

p-Coumaric acid501-98-4trans-4-Hydroxycinnamic acidEndogenous MetaboliteBacterialApoptosisAnti-inflammtoryA375B16melanomaPreneoplastic lesionsNephrotoxicityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
p-Coumaric acid
Cat. No.:
HY-N0351
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.